PMID- 23121603
OWN - NLM
STAT- MEDLINE
DCOM- 20130418
LR  - 20191210
IS  - 1440-1827 (Electronic)
IS  - 1320-5463 (Linking)
VI  - 62
IP  - 11
DP  - 2012 Nov
TI  - Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in 
      breast and gastric cancer: comparison with immunohistochemistry (IHC) and 
      fluorescence in situ hybridization (FISH).
PG  - 728-34
LID - 10.1111/j.1440-1827.2012.02862.x [doi]
AB  - The chromogenic in situ hybridization (CISH) assay, designed to detect the 
      amplification of the HER2 gene in formalin-fixed, paraffin-embedded (FFPE) breast 
      cancer (BC) and gastric cancer (GC) tissue specimens, was evaluated in 125 FFPE 
      BC cases and 198 FFPE GC cases for which the HER2 status had been predetermined 
      using immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). 
      In the 125 BC cases and the 198 gastric cases, we found a very good concordance 
      (98.4% and 99.0%, respectively) between CISH and FISH. In particular, we 
      evaluated the polysomy cases, as these cases often have ambiguous treatment 
      options in clinical practice. The polysomy of chromosome 17 was defined as the 
      presence of three or more CEP17 signals in at least 10% of the tumor cells. In 
      the 50 BC cases and 54 GC cases displaying chromosome 17 polysomy, the 
      concordance between FISH and CISH was 98.0% and 98.1%, respectively. These 
      results indicate that CISH could provide an accurate and practical alternative to 
      FISH for the clinical diagnosis of HER2 gene amplification in FFPE BC and FFPE GC 
      samples.
CI  - (c) 2012 The Authors. Pathology International (c) 2012 Japanese Society of Pathology 
      and Wiley Publishing Asia Pty Ltd.
FAU - Kiyose, Shinichiro
AU  - Kiyose S
AD  - Department of Tumor Pathology, Hamamatsu University School of Medicine, Japan.
FAU - Igarashi, Hisaki
AU  - Igarashi H
FAU - Nagura, Kiyoko
AU  - Nagura K
FAU - Kamo, Takaharu
AU  - Kamo T
FAU - Kawane, Kazunori
AU  - Kawane K
FAU - Mori, Hiroki
AU  - Mori H
FAU - Ozawa, Takachika
AU  - Ozawa T
FAU - Maeda, Matsuyoshi
AU  - Maeda M
FAU - Konno, Keisuke
AU  - Konno K
FAU - Hoshino, Hideaki
AU  - Hoshino H
FAU - Konno, Hiroyuki
AU  - Konno H
FAU - Ogura, Hiroyuki
AU  - Ogura H
FAU - Shinmura, Kazuya
AU  - Shinmura K
FAU - Hattori, Naohiko
AU  - Hattori N
FAU - Sugimura, Haruhiko
AU  - Sugimura H
LA  - eng
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Australia
TA  - Pathol Int
JT  - Pathology international
JID - 9431380
RN  - 0 (Biomarkers, Tumor)
RN  - 1HG84L3525 (Formaldehyde)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics/metabolism
MH  - Breast Neoplasms/*genetics/metabolism
MH  - Female
MH  - Formaldehyde
MH  - Gene Amplification
MH  - *Genes, erbB-2
MH  - Humans
MH  - Immunohistochemistry/*methods
MH  - In Situ Hybridization, Fluorescence/*methods
MH  - Paraffin Embedding
MH  - Predictive Value of Tests
MH  - Receptor, ErbB-2/*genetics/metabolism
MH  - Reproducibility of Results
MH  - Stomach Neoplasms/*genetics/metabolism
MH  - Tissue Array Analysis
MH  - Tissue Fixation
EDAT- 2012/11/06 06:00
MHDA- 2013/04/20 06:00
CRDT- 2012/11/06 06:00
PHST- 2012/11/06 06:00 [entrez]
PHST- 2012/11/06 06:00 [pubmed]
PHST- 2013/04/20 06:00 [medline]
AID - 10.1111/j.1440-1827.2012.02862.x [doi]
PST - ppublish
SO  - Pathol Int. 2012 Nov;62(11):728-34. doi: 10.1111/j.1440-1827.2012.02862.x.